Wednesday, March 7, 2012

Gilead four-in-one HIV drug passes another test

Gilead Sciences Inc.’s four-in-one quad pill for AIDS patients was as effective as its own three-in-one drug Atripla, but perhaps just as importantly didn’t increase cholesterol levels to the same levels.
The once-a-day pill from Foster City-based Gilead (NASDAQ: GILD) combines emtricitabine and tenofovir, which make up the Gilead therapy Truvada, and elvitegravir, which Gilead licensed from Japan Tobacco Inc., and a Gilead-developed booster called cobicistat.

No comments:

Post a Comment